Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • Nora AI
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Cellavision - Short term worries overshadow potential

CellaVision

Redeyes view on the Q4 report. The report was weak, and the challenges continue to affect the company negatively. We lower our expectations for 2023e as we do not see the difficulties fading in the short term. The development for the second half of 2022 was a reversal compared to a relatively solid development during the year’s first half. Considering the deviation from our expectations and continued headwinds going into 2023e, we have adjusted our estimates for 2023e and for the following years as well. With these changes, we decrease our Base case to SEK 280 (310) and fair value range to SEK 170 – 435 (200 – 470) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Cellavision - Short term worries overshadow potential

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.